Valuation : Exagen Inc.

Market Cap 169M 145M 137M 125M 233M 16.14B 235M 1.63B 628M 8.19B 634M 620M 26.01B P/E 2026 *
-10.7x
P/E 2027 * -13.8x
Enterprise Value 169M 145M 137M 125M 233M 16.14B 235M 1.63B 628M 8.19B 634M 620M 26.01B EV / Sales 2026 *
2.28x
EV / Sales 2027 * 2.07x
Free-Float
58.04%
Yield 2026 *
-
Yield 2027 * -
1 day-4.65%
1 week-7.56%
Current month-5.04%
1 month+4.97%
3 months+66.35%
6 months+114.46%
Current year+14.64%
1 week 6.83
Extreme 6.83
7.53
1 month 6.49
Extreme 6.49
7.99
Current year 2.59
Extreme 2.59
7.99
1 year 2.59
Extreme 2.59
12.23
3 years 1.3
Extreme 1.3003
12.23
5 years 1.3
Extreme 1.3003
14.9
10 years 1.3
Extreme 1.3003
29.86
Manager TitleAgeSince
Chief Executive Officer 41 16/10/2022
Director of Finance/CFO 57 31/08/2024
Chief Tech/Sci/R&D Officer - 22/06/2025
Director TitleAgeSince
Chairman 72 18/01/2023
Director/Board Member 63 29/07/2019
Director/Board Member 56 16/06/2021
Date Insider Type Main position Quantity % Market Cap. Importance
01/09/26 Sell

Chief Financial Officer

-22,185 0.0916%
12/03/26 Free

Chief Financial Officer

126,511 0.5582%
12/03/26 Free

Chief Executive Officer

250,000 1.1031%
Change 5-day change 1-year change 3-year change Capi.($)
-4.65%-7.56%-27.62%+191.63% 169M
-1.26%-0.47%+92.08%+501.73% 47.01B
-4.40%-7.40%+12.46%+50.98% 24.89B
-1.91%-2.76%-15.37%-38.61% 6.86B
+4.81%-0.46%+4.15%+146.45% 5.85B
-0.40%+1.68%+16.26%+71.90% 3.35B
-2.91%-3.92%-31.85%+1,713.39% 2.5B
-0.28%+0.86%+135.43%+29.58% 2.26B
+3.00%+4.28%+33.33%+47.09% 2.24B
-2.03%-1.81%-18.64%-56.41% 1.78B
Average -1.00%-1.22%+20.02%+265.77% 9.69B
Weighted average by Cap. -1.66%-1.08%+50.31%+310.42%

Financials

2026 *2027 *
Net sales 73.91M 63.57M 59.98M 54.64M 102M 7.07B 103M 714M 275M 3.58B 278M 271M 11.39B 81.41M 70.02M 66.06M 60.18M 113M 7.78B 114M 787M 303M 3.95B 306M 299M 12.54B
Net income -15.83M -13.62M -12.85M -11.7M -21.88M -1.51B -22.08M -153M -58.89M -768M -59.46M -58.16M -2.44B -13.08M -11.25M -10.61M -9.67M -18.07M -1.25B -18.24M -126M -48.65M -634M -49.12M -48.04M -2.01B
Net Debt - -
Logo Exagen Inc.
Exagen Inc. is a provider of autoimmune diagnostics focused on transforming care for patients with chronic and debilitating autoimmune conditions. The Company is focused on the design, development and commercialization of a portfolio of testing products under its AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related disease including, among others, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its testing products are supported by two proprietary technologies: its AVISE Lupus platform, which incorporates Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE, and a set of three biomarkers, the t-cell-based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into its AVISE CTD product. The Company’s flagship product, AVISE CTD, enables clinicians to more effectively diagnose complex autoimmune conditions.
Employees
218
Date Price Change Volume
10/09/26 US$6.970 -4.65% 197,464
09/09/26 US$7.310 +0.14% 149,096
08/09/26 US$7.300 -3.69% 151,905
04/09/26 US$7.580 +0.53% 138,172
03/09/26 US$7.540 +0.40% 294,818
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
6.970USD
Average target price
9.857USD
Spread / Average Target
+41.42%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!